NCT00444379View on ClinicalTrials.gov

Anti-Retrovirals for Kaposi's Sarcoma

PHASE4CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

February 29, 2012

Study Completion Date

July 31, 2012

Conditions
Kaposi's SarcomaHIV Infections
Interventions
DRUG

Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir

Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg

Trial Locations (1)

Unknown

Infectious Diseases Institute, Mulago Hospital, Kampala

Sponsors

Collaborators (2)

Gilead Sciences
Abbott
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Gilead Sciences

INDUSTRY

collaborator

Abbott

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, San Francisco

OTHER